Keyphrases
Pulmonary Hypertension
100%
Respiratory Syncytial Virus
100%
Soluble Suppression of Tumorigenicity 2 (sST2)
100%
Novel Therapeutic Targets
20%
Pathophysiological Mechanisms
20%
Endothelial Nitric Oxide Synthase Uncoupling
20%
Pulmonary Artery Acceleration Time
20%
Pathogenic Role
10%
Wild Mice
10%
Periostin (POSTN)
10%
Reinfection
10%
Interleukin-13 (IL-13)
10%
Right Ventricle
10%
Bioactivity
10%
Arginase-1 (Arg-1)
10%
Neonatal Mice
10%
Time Ratio
10%
Systolic Pressure
10%
Arginase
10%
Ejection Time
10%
Arginase 2
10%
Respiratory Syncytial Virus Bronchiolitis
10%
Children with Congenital Heart Disease
10%
Translational Mouse Model
10%
Type 2 Immunity
10%
Medicine and Dentistry
Carcinogenicity
100%
Pulmonary Hypertension
100%
Human Respiratory Syncytial Virus
100%
Pulmonary Artery
18%
Nitric Oxide Synthase
18%
Epileptic Absence
9%
Reinfection
9%
Transcription Factor RUNX2
9%
Systolic Blood Pressure
9%
Right Ventricle
9%
Biological Activity
9%
Persistent Truncus Arteriosus
9%
Interleukin 13
9%
Bronchiolitis
9%
Arginase 1
9%
Arginase
9%
Heart Ventricle Ejection Time
9%
Pharmacology, Toxicology and Pharmaceutical Science
Carcinogenicity
100%
Pulmonary Hypertension
100%
Human Respiratory Syncytial Virus
100%
Mouse
18%
Nitric Oxide Synthase
18%
Mouse Model
9%
Epileptic Absence
9%
Wild Type Mouse
9%
Transcription Factor RUNX2
9%
Interleukin 13
9%
Reinfection
9%
Arginase 1
9%
Congenital Heart Disease
9%
Arginase
9%
Bronchiolitis
9%
Immunology and Microbiology
Human Respiratory Syncytial Virus
100%
Mouse
18%
Pulmonary Artery
18%
Biological Activity
9%
Wild Type
9%
Mouse Model
9%
Bronchiolitis
9%
Wild Type Mouse
9%
Transcription Factor RUNX2
9%
Interleukin 13
9%
Systolic Blood Pressure
9%
Heart Ventricle Ejection Time
9%